Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy

Table 1 Results of hepatitis B virus reactivation in patients with hepatocellular carcinoma receiving chemotherapy n (%)

Ref.	No of patients	Chemotherapy	No of sessions	HBV reactivation (hepatitis)1	Morbidity/mortality
Nagamatsu et al[29]	33	TAI	Weekly infusion	24%	3 died
Jang et al[27]	146	TACL	5 (2-14)	33.7% (21.7%)	25 resolved, 3 died
Nagamatsu et al[10]	17	TAI	bi-weekly infusion	67%	3 died of HBV reactivation
Yeo et al[15]	102	Systemic chemotherapy	3-weekly intervals	(36%)	Twelve died of HBV reactivation
Park et al[31]	89	TACE	1	4.3%	3 resolved, 1 had tumor-related hepatic failure
Jang et al[17]	73	TACL	1-monthly intervals	40.5% (29.7%)	One died of HBV reactivation
Kim et al[6]	91	TACE + RT	NA	21.8% (a rebound of HBV DNA to > 100 × baseline)	4 (12.5) developed CHB exacerbation
Lao et al[32]	172	TACE	1.3/person	14.5%	12.1% in the reactivation group had CHB exacerbation
Jang et al[7]	205	LAT, TACL, TACL + RT	1-2 monthly intervals	30.2%	10 developed decompensation, 1 died
Lao et al[30]	320	TACE	4-10 weekly intervals	17.5%	26 (8.1) had liver functional deterioration

¹The rates of hepatitis B virus (HBV) reactivation were the frequencies in antiviral-untreated patients. Modified from Jang et al[8]. HCC: Hepatocellular carcinoma; TAI: Transarterial infusion chemotherapy; TACL: Transarterial chemo-lipiodolization; TACE: Transarterial chemo-embolization; RT: Radiotherapy; LAT: Local ablation therapy.